Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with high recurrence risk. Currently, neoadjuvant chemotherapy (NAC) serves as the core therapeutic option for TNBC, which requires effective biomarkers to predict patient prognosis. As the key component of the tumor immune microenvironment (TIME) in the tumor microenvironment (TME), Tumor-infiltrating lymphocytes (TILs) have been confirmed to be correlated with NAC prognosis of TNBC by existing studies, yet most of these studies focus only on patients with early-stage TNBC. In addition, no unified interpretation standard has been established. This review reveals the cellular composition of TILs and the anti-tumor immune mechanisms of TILs subsets, summarizes the internationally quantitative evaluation criteria and published clinical research findings and confirms that stromal tumor-infiltrating lymphocytes (sTILs) can facilitate the prediction of the patients prognosis receiving NAC. This review provides a theoretical support for the application of TILs in the precise stratified treatment of TNBC and the efficacy evaluation of new drugs. At present, in-depth research is still needed to clarify the immune pathway mechanisms of each TIL subset, improve stage-specific research, and standardize the interpretation and assessment of TILs. In future research, artificial intelligence can be applied to optimize detection standards, and large-sample clinical trials should be carried out to further explore the clinical potential of TILs.
No takes yet. Share an insight, caveat, or question.
Yuan Xu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: